pubrio
Intercell AG

Intercell AG

France · Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. We take a highly specialized and targeted approach to vaccine development by focusing on vaccine solutions addressing unmet medical needs to ensure we can make a difference to peoples' lives. We apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, and our established vaccine development capabilities, to develop vaccines against diseases which are not yet vaccine-preventable, or for which there are limited effective treatment options. Today, we are leveraging our expertise and capabilities to rapidly advance a broad range of vaccines into and through the clinic, including candidates against the chikungunya virus and Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with ~700 employees.

Company Insights
Company Overview

2013

Founded

Research

Industry

France

Location

1,336,102

Ranking

800 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Intercell AG

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​